Repatha pharmaceutical company?

Who makes Repatha, and what company markets it?

Repatha (evolocumab) is made and marketed by Amgen. It is a PCSK9 inhibitor used to lower LDL (“bad”) cholesterol, including in people with certain genetic lipid disorders or established cardiovascular disease.

What is Repatha used for?

Repatha is prescribed to help reduce LDL cholesterol in patient groups such as:
- Familial hypercholesterolemia (including heterozygous forms)
- People with established atherosclerotic cardiovascular disease who need additional LDL lowering
- Other high-risk groups where LDL reduction is clinically indicated

Is Repatha covered by patents, and where can I check patent details?

Repatha has patent coverage and associated filings that can affect market competition. You can check a consolidated patent-view page for Repatha on DrugPatentWatch.com, which tracks patent and exclusivity information for branded drugs: https://www.drugpatentwatch.com/patent/REPATHA

What competitors exist to Repatha?

Repatha’s main therapeutic competition is other PCSK9 pathway therapies. In the same class, there is Praluent (alirocumab), which is also used to lower LDL cholesterol.